Horizon Pharma expects additional US patent for VIMOVO (naproxen/esomeprazole) delayed release tablets.
M2 PHARMA-October 28, 2015-Horizon Pharma expects additional US patent for VIMOVO (naproxen/esomeprazole) delayed release tablets
(C)2015 M2 COMMUNICATIONS
Biopharmaceutical company Horizon Pharma (NASDAQ:HZNP) disclosed on Tuesday the receipt of a Notice of Allowance for US patent application entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that covers the US approved medicine VIMOVO (naproxen/esomeprazole) delayed release tablets.
The company's US patent, with application number 14/753,195 (US publication number 2015-0297543), scheduled to issue from this application will expire in May 2022.
Following issuance, Horizon and POZEN intend to list the patent in the US FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
In conjunction, this will be the 12 US patent to be listed in the Orange Book for VIMOVO, according to the company.
VIMOVO (naproxen/esomeprazole magnesium) is a fixed-dose combination of delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID), and immediate-release esomeprazole magnesium, a stomach acid-reducing proton pump inhibitor (PPI), approved for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers, concluded the company.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 28, 2015|
|Previous Article:||Sagent Pharmaceuticals unveils Chlorothiazide Sodium for Injection, USP in patients with edema.|
|Next Article:||Nephros submits S100 Ultrafilter to US FDA for control of infection in medical facilities.|